Monique Allaire: Ledger

Stories naming Monique Allaire. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
	THRUST Strategic Communications	Brandon BioCatalyst portfolio, Brandon Capital portfolio

Key hire

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.

Brandon Capital portfolio 12 May 2022 Amylin Biosplice Therapeutics Elcelyx Therapeutics Glyscend Johns Hopkins University THRUST Strategic Communications Ashish Nimgaonkar, M.D.Mark Fineman, Ph.D.Monique Allaire

Monique Allaire

Roles

Coverage

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment